Inhibrx Biosciences, Inc. (INBX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$90.43

From 52W high−36.70%

Volume156060.00

Market cap$1.32B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$90.43

From 52W high

−36.70%

Volume

156060.00

Market cap

$1.32B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−9.9x

P/E (TTM)

—

RSI (14)

39.2

MomentumView details →

1D Return

−0.04%

YTD Return

+14.00%

SummaryUpdated Jun 1, 2026

Inhibrx Biosciences, Inc. (NASDAQ:INBX) is a clinical-stage biopharmaceutical company founded in 2024 and based in La Jolla, California. The company went public on June 4, 2024, representing a spinoff from its parent company Inhibrx, Inc. Inhibrx Biosciences focuses on developing innovative biologic therapeutics for patients with life-threatening conditions, particularly in oncology. The company operates as a pure-play biotechnology firm dedicated to advancing two primary drug candidates through clinical trials.

Ask drillr about Inhibrx Biosciences, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−9.9x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

−24.9x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

260.83%

ROA (TTM)

−89.60%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+17.78%

FCF YoY

+5.90%

Revenue CAGR 3Y

−15.98%

EPS CAGR 3Y

—

EBITDA YoY

+22.33%

MomentumView details →

1D Return

−0.04%

YTD Return

+14.00%

1Y Return

+135.63%

RSI (14)

39.2

vs 50D SMA

−13.19%

vs 200D SMA

−1.67%

Capital & dividendView details →

Debt/Equity

−0.10x

Current Ratio

5.07x

Quick Ratio

5.07x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$2.34

EPS Surprise

−2.63%

Beats (12Q)

4/12

Next Q EPS Est

−$2.70

Avg Surprise (4Q)

−1.10%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−138.18M

Op. CF (TTM)

−131.89M

Next earningsNov 13, 2026 →

Latest newsMore news →

Inhibrx announced that its experimental OX40-targeting immunotherapy showed responses in patients with head and neck cancer, particularly in a subset with HPV-positive tumors.42d ago

Inhibrx entered into an amended loan agreement with Oxford Finance, expanding the total facility to $500.0 million and receiving an initial $100.0 million tranche.96d ago

Similar companies

ORIC Pharmaceuticals, Inc.ORIC Tyra Biosciences, Inc.TYRA First Tracks Biotherapeutics IncTRAX Taysha Gene Therapies, Inc.TSHA Rapport Therapeutics, Inc. Common StockRAPP Ocular Therapeutix, Inc.OCUL Find similar companies →

Latest newsMore news →

Inhibrx announced that its experimental OX40-targeting immunotherapy showed responses in patients with head and neck cancer, particularly in a subset with HPV-positive tumors.42d ago Inhibrx entered into an amended loan agreement with Oxford Finance, expanding the total facility to $500.0 million and receiving an initial $100.0 million tranche.96d ago